The underlying mechanism for increased levels of sPD-1 after certain modalities of treatment (radiotherapy, anti-EGFR therapy, and anti-PD-1 immunotherapy) may be the reactivation of tumor-specific cytotoxic T-lymphocytes [36]. The gene discussed is HOXD13; the disease is neoplasm.